|Day's range||271.20 - 279.40|
|52-week range||232.00 - 333.65|
|PE ratio (TTM)||16.99|
|Earnings date||25 Jul 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||318.60|
When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...
ZUG, Switzerland--(BUSINESSWIRE)-- If approved, IMRALDI would be the third anti-TNF biosimilar in Biogen’s portfolio in Europe, helping to expand affordable therapy options and increase access for patients ...